Persistent Multiyear Control of Relapsed T-Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report

Research output: Contribution to journalArticle

Abstract

There are few therapeutic options for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have recurrent disease after initial matched sibling hematopoietic stem cell transplantation. While a second hematopoietic stem cell transplant (HSCT) from a haploidentical donor offers the conceptual possibility of greater graft versus leukemia effect, there is minimal literature to describe the efficacy of this approach in recurrent pediatric T-ALL. We present the case of a now 9-year-old female in whom second haploidentical HSCT, followed by successive donor lymphocyte infusions in response to minimal residual disease reemergence, has led to 3+ years of ongoing disease control without graft versus host disease and excellent quality of life.

Original languageEnglish (US)
JournalPediatric Blood and Cancer
DOIs
StateAccepted/In press - 2016

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Tissue Donors
Lymphocytes
Hematopoietic Stem Cells
Transplants
Hematopoietic Stem Cell Transplantation
Residual Neoplasm
Graft vs Host Disease
Siblings
Leukemia
Quality of Life
Pediatrics
Therapeutics

Keywords

  • Donor lymphocyte infusion
  • Haploidentical bone marrow transplant
  • Relapse
  • T-cell acute lymphoblastic leukemia

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

@article{9498bd2db48e4f56a8c58f383e4d80c9,
title = "Persistent Multiyear Control of Relapsed T-Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report",
abstract = "There are few therapeutic options for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have recurrent disease after initial matched sibling hematopoietic stem cell transplantation. While a second hematopoietic stem cell transplant (HSCT) from a haploidentical donor offers the conceptual possibility of greater graft versus leukemia effect, there is minimal literature to describe the efficacy of this approach in recurrent pediatric T-ALL. We present the case of a now 9-year-old female in whom second haploidentical HSCT, followed by successive donor lymphocyte infusions in response to minimal residual disease reemergence, has led to 3+ years of ongoing disease control without graft versus host disease and excellent quality of life.",
keywords = "Donor lymphocyte infusion, Haploidentical bone marrow transplant, Relapse, T-cell acute lymphoblastic leukemia",
author = "Jeffrey Huo and Heather Symons and Nancy Robey and Borowitz, {Michael J} and Schafer, {Eric S.} and Chen, {Allen R}",
year = "2016",
doi = "10.1002/pbc.25971",
language = "English (US)",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Persistent Multiyear Control of Relapsed T-Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions

T2 - A Case Report

AU - Huo, Jeffrey

AU - Symons, Heather

AU - Robey, Nancy

AU - Borowitz, Michael J

AU - Schafer, Eric S.

AU - Chen, Allen R

PY - 2016

Y1 - 2016

N2 - There are few therapeutic options for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have recurrent disease after initial matched sibling hematopoietic stem cell transplantation. While a second hematopoietic stem cell transplant (HSCT) from a haploidentical donor offers the conceptual possibility of greater graft versus leukemia effect, there is minimal literature to describe the efficacy of this approach in recurrent pediatric T-ALL. We present the case of a now 9-year-old female in whom second haploidentical HSCT, followed by successive donor lymphocyte infusions in response to minimal residual disease reemergence, has led to 3+ years of ongoing disease control without graft versus host disease and excellent quality of life.

AB - There are few therapeutic options for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have recurrent disease after initial matched sibling hematopoietic stem cell transplantation. While a second hematopoietic stem cell transplant (HSCT) from a haploidentical donor offers the conceptual possibility of greater graft versus leukemia effect, there is minimal literature to describe the efficacy of this approach in recurrent pediatric T-ALL. We present the case of a now 9-year-old female in whom second haploidentical HSCT, followed by successive donor lymphocyte infusions in response to minimal residual disease reemergence, has led to 3+ years of ongoing disease control without graft versus host disease and excellent quality of life.

KW - Donor lymphocyte infusion

KW - Haploidentical bone marrow transplant

KW - Relapse

KW - T-cell acute lymphoblastic leukemia

UR - http://www.scopus.com/inward/record.url?scp=84960968970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960968970&partnerID=8YFLogxK

U2 - 10.1002/pbc.25971

DO - 10.1002/pbc.25971

M3 - Article

C2 - 26990138

AN - SCOPUS:84960968970

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

ER -